Review
Clinical Epidemiology of Coronavirus Disease 2019 Open
Access
--Defined
on Current Research
Fengyu
Zhang and Claude Hughes
July 25, 2020
Coronavirus disease 2019 (COVID-19) is a new infectious
respiratory disease that has caused the ongoing global pandemic. The primary
purpose of this article is to describe evolving clinical epidemiology of
COVID-19, including 1) infection and testing, 2) clinical spectrum including classification
of clinical type, asymptomatic cases, severe cases and comorbidity, and clinical
and immunological response, 3) regional variation in clinical presentation, 4) population
distribution by age, sex, and occupation, and finally, 5) case-fatality. This
content may provide important information on detailed clinical type and presentation
of the disease, in which appropriate clinical outcomes can be derived for
developing prevention strategies and clinical studies or trials that aim to
test potential therapeutics or products for different patient populations.
Keywords:
Clinical epidemiology; COVID-19; SARS-CoV2
Copyright©2020 by the author(s).
Licensee Global
Clinical and Translational Research. This is an open-access article
distributed under the terms and conditions of the Creative Commons Attribution
License (CCBY4.0,https://creative-commons.org/licenses/by/4.0/),whichpermits unrestricted
use, distribution, and reproduction in any medium provided the original work is
properly cited.
How
to cite this article:
Zhang F and Hughes C. Clinical
epidemiology of coronavirus disease 2019: defined on current research. Glob
Clin Transl Res. 2020; 2 (3): 54-72.
DOI:10.36316/gcatr.02.0032
REFERENCES
1.
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L,
Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of
probable bat origin. Nature. 2020;579(7798):270-3.
2.
Kim J-M, Chung Y-S, Jo HJ, Lee N-J, Kim MS, Woo
SH, et al. Identification of Coronavirus Isolated from a Patient in Korea with
COVID-19. Osong Public Health Res Perspect. 2020; 11(1):3-7.
3.
Andersen KG, Rambaut A, Lipkin WI, Holmes EC,
Garry RF. The proximal origin of SARS-CoV2. Nature Medicine. 2020; 26:450-2.
4.
Paules CI, Marston HD, Fauci AS. Coronavirus
infections—more than just the common cold. Jama. 2020;323(8):707-8.
5.
Lipsitch M, Swerdlow DL, Finelli L. Defining the
Epidemi-ology of Covid-19 - Studies Needed. N Engl J Med. 2020; 382(13):1194-6.
6.
Furukawa NW, Brooks JT, Sobel J. Evidence
Supporting Trans-mission of Severe Acute Respiratory Syndrome Coronavirus 2
While Presymptomatic or Asymptomatic. Emerg Infect Dis. 2020;26(7).
7.
Gandhi M, Yokoe DS, Havlir DV. Asymptomatic
Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N
Engl J Med. 2020;382(22):2158-60.
8.
Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et
al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA.
2020;323(14):1406-7.
9.
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J,
et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2
infections. Nat Med. 2020.
10.
Oran DP, Topol EJ. Prevalence of Asymptomatic
SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020.
11.
The National Health Commission. Guidance to the
control and treatment for COVID-19
12.
Centers for Disease Control and Prevention. CDC
2019-Novel Coronavirus (2019-nCov) Real-Time RT-PCR DIagnostic Panel. https://wwwfdagov/media/134922/download.
2020.
13.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New
England Journal of Medicine. 2020.
14.
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al.
Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4).
15.
Waller JV, Kaur P, Tucker A, Lin KK, Diaz MJ,
Henry TS, et al. Diagnostic Tools for Coronavirus Disease (COVID-19): Comparing
CT and RT-PCR Viral Nucleic Acid Testing. AJR Am J Roentgenol. 2020:1-5.
16.
Pan Y, Long L, Zhang D, Yuan T, Cui S, Yang P, et
al. Potential False-Negative Nucleic Acid Testing Results for Severe Acute
Respiratory Syndrome Coronavirus 2 from Thermal Inacti-vation of Samples with
Low Viral Loads. Clin Chem. 2020; 66(6):794-801.
17.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb
L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of
COVID-19: results of an open-label non-randomized clinical trial. Int J
Antimicrob Agents. 2020:105949.
18.
The National Health Commision. Diagnosis and
Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med
J (Engl). 2020;133(9):1087-95.
19.
Mizumoto K, Kagaya K, Zarebski A, Chowell G.
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19)
cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro
Surveill. 2020;25(10).
20.
Barrett ES, Horton DB, Roy J, Gennaro ML, Brooks
A, Tischfield J, et al. Prevalence of SARS-CoV-2 infection in previously
undiagnosed health care workers at the onset of the U.S. COVID-19 epidemic.
medRxiv. 2020.
21.
Arons MM, Hatfield KM, Reddy SC, Kimball A, James
A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Trans-mission in
a Skilled Nursing Facility. N Engl J Med. 2020; 382(22):2081-90.
22.
Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence
of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston.
JAMA. 2020.
23.
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al.
SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-5.
24.
Lavezzo E, Franchin E, Ciavarella C,
Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of COVID-19
outbreak in the municipality of Vo, Italy. medRxiv. 2020: 2020.04.17.20053157.
25.
Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC.
Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection
with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062-6.
26.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et
al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
2019. Clin Infect Dis. 2020.
27.
Yan M, Zheng Y, Sun Y, Wang L, Luan L, Liu J, et
al. Analysis of the diagnostic value of serum specific antibody testing for
coronavirus disease 2019. J Med Virol. 2020.
28.
Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al.
Development and clinical application of a rapid IgM-IgG combined antibody test
for SARS-CoV-2 infection diagnosis. J Med Virol. 2020.
29.
Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau
HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody
assays. J Clin Virol. 2020;129:104480.
30.
Theel ES, Slev P, Wheeler S, Couturier MR, Wong
SJ, Kadkhoda K. The Role of Antibody Testing for SARS-CoV-2: Is There One? J
Clin Microbiol. 2020.
31.
The Food and Drug Administration. SARS-CoV-2
antibody tests-Revocation of EUA.
https://wwwfdagov/media/140351/download.
2020.
32.
Andersson M, Low N, French N, Greenhalgh T,
Jeffery K, Brent A, et al. Rapid roll out of SARS-CoV-2 antibody testing-a
concern. BMJ. 2020;369:m2420.
33.
Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al.
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in
China. Nat Med. 2020.
34.
Bryan A, Pepper G, Wener MH, Fink SL, Morishima C,
Chaudhary A, et al. Performance Characteristics of the Abbott Architect
SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol.
2020.
35.
Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo
J, Hernan MA, Perez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain
(ENE-COVID): a nationwide, population-based sero-epidemiological study. Lancet.
2020.
36.
Stringhini S, Wisniak A, Piumatti G, Azman AS,
Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in
Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020.
37.
Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al.
Epidemiological characteristics of 2143 pediatric patients with 2019
coronavirus disease in China. Pediatrics. 2020.
38.
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team.
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus
Diseases (COVID-19) — China, 2020. China CDC Weekly. 2020;2(8).
39.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et
al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J
Med. 2020.
40.
Lechien JR, Chiesa-Estomba CM, Place S, Van
Laethem Y, Cabaraux P, Mat Q, et al. Clinical and Epidemiological Chara-cteristics
of 1,420 European Patients with mild-to-moderate Coronavirus Disease 2019. J
Intern Med. 2020.
41.
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate
and Chara-cteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA.
2020;323(18):1775-6.
42.
Zhang F, Hughes C. A Caution in Association of ABO
Blood Group with COVID-19. Global Clinical and Translational Research.
2020;2(1):51-3.
43.
Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et
al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis.
2020;20(6):656-7.
44.
Jung F, Krieger V, Hufert FT, Kupper JH. Herd
immunity or suppression strategy to combat COVID-19. Clin Hemorheol Microcirc.
2020.
45.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.
Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
2020;395(10229):1054-62.
46.
Park JH, Jang W, Kim SW, Lee J, Lim YS, Cho CG, et
al. The Clinical Manifestations and Chest Computed Tomography Findings of
Coronavirus Disease 2019 (COVID-19) Patients in China: A Proportion
Meta-Analysis. Clin Exp Otorhino-laryngol. 2020;13(2):95-105.
47.
Vonck K, Garrez I, De Herdt V, Hemelsoet D,
Laureys G, Raedt R, et al. Neurological manifestations and neuro-invasive
mechanisms of the severe acute respiratory syndrome coronavirus type 2. Eur J
Neurol. 2020.
48.
Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K.
Neurological manifestations of COVID-19 and other coronavirus infections: A
systematic review. Clin Neurol Neurosurg. 2020;194: 105921.
49.
Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL,
Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with
overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr
Comp Physiol. 2007;292(1):R373-81.
50.
Alenina N, Bader M. ACE2 in Brain Physiology and
Patho-physiology: Evidence from Transgenic Animal Models. Neurochem Res.
2019;44(6):1323-9.
51.
Xu Z, Xie C, Xia L, Yuan Y, Zhu H, Huang X, et al.
Targeted exome sequencing identifies five novel loci at genome-wide
significance for modulating antidepressant response in patients with major
depressive disorder. Transl Psychiatry. 2020;10(1):30.
52.
Luers JC, Rokohl AC, Loreck N, Wawer Matos PA,
Augustin M, Dewald F, et al. Olfactory and Gustatory Dysfunction in Coronavirus
Disease 19 (COVID-19). Clin Infect Dis. 2020.
53.
Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde
AS. Associ-ation of chemosensory dysfunction and COVID-19 in patients
presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020.
54.
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi
M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a
clinical presentation of mild-to-moderate forms of the coronavirus disease
(COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020.
55.
Giacomelli A, Pezzati L, Conti F, Bernacchia D,
Siano M, Oreni L. Self-reported olfactory and taste disorders in SARS-CoV-2
patients: a cross-sectional study [published online March 26, 2020]. Clin
Infect Dis. 2020.
56.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al.
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease
2019 in Wuhan, China. JAMA Neurol. 2020.
57.
Passali GC, Bentivoglio AR. Comment to the article
"Olfactory and gustatory dysfunctions as a clinical presentation of
mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter
European study". Eur Arch Otorhinolaryngol. 2020.
58.
Vaira LA, Hopkins C, Salzano G, Petrocelli M,
Melis A, Cucur-ullo M, et al. Olfactory and gustatory function impairment in
COVID-19 patients: Italian objective multicenter-study. Head Neck. 2020.
59.
Tsuruoka S, Wakaumi M, Araki N, Ioka T, Sugimoto
K, Fuji-mura A. Comparative study of taste disturbance by losartan and
perindopril in healthy volunteers. J Clin Pharmacol. 2005;45(11):1319-23.
60.
Vaira LA, Salzano G, Fois AG, Piombino P, De Riu
G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int
Forum Allergy Rhinol. 2020.
61.
Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van
den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes
in the olfactory system suggests mechanisms underlying COVID-19-associated
anosmia. bioRxiv. 2020: 2020.03.25.009084.
62.
Fantini J, Di Scala C, Chahinian H, Yahi N.
Structural and molecular modelling studies reveal a new mechanism of action of
chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J
Antimicrob Agents. 2020;55(5):105960.
63.
Mocchetti I. Exogenous gangliosides, neuronal
plasticity and repair, and the neurotrophins. Cell Mol Life Sci.
2005;62(19-20):2283-94.
64.
Milanetti E, Miotto M, Rienzo LD, Monti M, Gosti
G, Ruocco G. In-Silico evidence for two receptors based strategy of SARS-CoV-2.
bioRxiv. 2020:2020.03.24.006197.
65.
Torabi A, Mohammadbagheri E, Akbari Dilmaghani N,
Bayat AH, Fathi M, Vakili K, et al. Proinflammatory Cytokines in the Olfactory
Mucosa Result in COVID-19 Induced Anosmia. ACS Chem Neurosci.
2020;11(13):1909-13.
66.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
China. Lancet. 2020;395(10223):497-506.
67.
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et
al. Clinical findings in a group of patients infected with the 2019 novel
coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.
BMJ. 2020;368:m606.
68.
Pongpirul WA, Mott JA, Woodring JV, Uyeki TM,
MacArthur JR, Vachiraphan A, et al. Clinical Characteristics of Patients
Hospitalized with Coronavirus Disease, Thailand. Emerg Infect Dis. 2020;26(7).
69.
Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha
G, et al. Clinical and epidemiologic profile of the initial COVID-19 patients
at a tertiary care centre in India. Monaldi Arch Chest Dis. 2020;90(1).
70.
Covid-19 National Emergency Response Center E,
Case Management Team KCfDC, Prevention. Early Epidemiological and Clinical
Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public
Health Res Perspect. 2020;11(1):8-14.
71.
Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K,
Nagamine K, et al. Clinical course of 2019 novel coronavirus disease (COVID-19)
in individuals present during the outbreak on the Diamond Princess cruise ship.
J Infect Chemother. 2020.
72.
Covid- Investigation Team. Clinical and virologic
characteristics of the first 12 patients with coronavirus disease 2019
(COVID-19) in the United States. Nat Med. 2020.
73.
Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C,
Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes
of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report
from the United States. Diagnosis (Berl). 2020;7(2):91-6.
74.
Argenziano MG, Bruce SL, Slater CL, Tiao JR,
Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000
patients with coronavirus disease 2019 in New York: retrospective case series.
BMJ. 2020;369:m1996.
75.
Colaneri M, Sacchi P, Zuccaro V, Biscarini S,
Sachs M, Roda S, et al. Clinical characteristics of coronavirus disease
(COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to
28 February 2020. Euro Surveill. 2020;25(16).
76.
Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran
E, MacGowan A. Clinical features of 95 sequential hospitalised patients with
novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect. 2020.
77.
Schwartz DA, Graham AL. Potential Maternal and
Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women:
Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses.
2020;12(2).
78.
Eppes C, Rac M, Dunn J, Versalovic J, Murray KO,
Suter MA, et al. Testing for Zika virus infection in pregnancy: key concepts to
deal with an emerging epidemic. Am J Obstet Gynecol. 2017;216(3):209-25.
79.
Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC,
et al. Pregnancy and perinatal outcomes of women with severe acute respiratory
syndrome. Am J Obstet Gynecol. 2004;191(1):292-7.
80.
Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y.
Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. J
Med Virol. 2020.
81.
81. Chen
S, Huang B, Luo DJ, Li X, Yang F, Zhao Y, et al. [Pregnancy with new
coronavirus infection: clinical characteristics and placental pathological
analysis of three cases]. Zhonghua Bing Li Xue Za Zhi. 2020;49(5):418-23.
82.
Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et
al. Clinical characteristics and intrauterine vertical transmission poten-tial
of COVID-19 infection in nine pregnant women: a retro-spective review of
medical records. Lancet. 2020; 395 (10226):809-15.
83.
Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L,
Marin E, Perez-Medina T. Clinical course of Coronavirus Disease-2019 (COVID-19)
in pregnancy. Acta Obstet Gynecol Scand. 2020.
84.
Liu Y, Chen H, Tang K, Guo Y. Clinical
manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect.
2020.
85.
Savasi VM, Parisi F, Patane L, Ferrazzi E,
Frigerio L, Pellegrino A, et al. Clinical Findings and Disease Severity in
Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). Obstet
Gynecol. 2020.
86.
Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel
Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China.
JAMA. 2020.
87.
Kamali Aghdam M, Jafari N, Eftekhari K. Novel
coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case
report. Infect Dis (Lond). 2020;52(6):427-9.
88.
Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x,
et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New
England Journal of Medicine. 2020.
89.
Wu Z, McGoogan JM. Characteristics of and
Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in
China: Summary of a Report of 72314 Cases From the Chinese Center for Disease
Control and Prevention. JAMA. 2020.
90.
Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2
infection in children: Transmission dynamics and clinical characteristics. J
Formos Med Assoc. 2020;119(3):670-3.
91.
Choi SH, Kim HW, Kang JM, Kim DH, Cho EY.
Epidemiology and clinical features of coronavirus disease 2019 in children.
Clin Exp Pediatr. 2020;63(4):125-32.
92.
Arons MM, Hatfield KM, Reddy SC, Kimball A, James
A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Trans-mission in
a Skilled Nursing Facility. N Engl J Med. 2020; 382(22):2081-90.
93.
Bai K, Liu W, Liu C, Fu Y, Hu J, Qin Y, et al.
Clinical Analysis of 25 COVID-19 Infections in Children. Pediatr Infect Dis J.
2020;39(7):e100-e3.
94.
Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D.
Clinical and epidemiological features of 36 children with coronavirus disease
2019 (COVID-19) in Zhejiang, China: an obser-vational cohort study. Lancet
Infect Dis. 2020.
95.
Zimmermann P, Curtis N. Coronavirus Infections in
Children Including COVID-19: An Overview of the Epidemiology, Clinical
Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr
Infect Dis J. 2020;39(5):355-68.
96.
Chao JY, Derespina KR, Herold BC, Goldman DL,
Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of
Hospitalized and Critically Ill Children and Adolescents with Coronavirus
Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J
Pediatr. 2020.
97.
Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical
characteristics and outcomes of older patients with corona-virus disease 2019
(COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J
Gerontol A Biol Sci Med Sci. 2020.
98.
Etard JF, Vanhems P, Atlani-Duault L, Ecochard R.
Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly
in retirement homes and long-term facilities, France, March 2020. Euro
Surveill. 2020;25(15).
99.
Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al.
Sex-specific clinical characteristics and prognosis of coronavirus disease-19
infection in Wuhan, China: A retrospective study of 168 severe patients. PLoS
Pathog. 2020;16(4):e1008520.
100. Michelozzi
P, de'Donato F, Scortichini M, De Sario M, Noccioli F, Rossi P, et al.
Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and
age: rapid mortality survei-llance system, Italy, 1 February to 18 April 2020.
Euro Surveill. 2020;25(19).
101. Takahashi
T, Wong P, Ellingson M, Lucas C, Klein J, Israelow B, et al. Sex differences in
immune responses to SARS-CoV-2 that underlie disease outcomes. medRxiv. 2020.
102. Klein
SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.
2016;16(10):626-38.
103. Conti
P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical
response to viral infection. J Biol Regul Homeost Agents. 2020;34(2).
104. Jansen
A, Chiew M, Konings F, Lee CK, Ailan L. Sex matters - a preliminary analysis of
Middle East respiratory syndrome in the Republic of Korea, 2015. Western Pac
Surveill Response J. 2015;6(3):68-71.
105. Channappanavar
R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences
in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J
Immunol. 2017;198(10):4046-53.
106. Gagliardi
MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in
COVID-19. Cell Death Discov. 2020;6:37.
107. Kluytmans-van
den Bergh MFQ, Buiting AGM, Pas SD, Bentvelsen RG, van den Bijllaardt W, van
Oudheusden AJG, et al. Prevalence and Clinical Presentation of Health Care
Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During
an Early Phase of the Pandemic. JAMA Netw Open. 2020;3(5):e209673.
108. Liu M,
He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. [Clinical characteristics of 30
medical workers infected with new coronavirus pneumonia]. Zhonghua Jie He He Hu
Xi Za Zhi. 2020;43(3):209-14.
109. Russell
TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al.
Estimating the infection and case fatality ratio for coronavirus disease
(COVID-19) using age-adjusted data from the outbreak on the Diamond Princess
cruise ship, February 2020. Euro Surveill. 2020;25(12).
110. Word
Health Organization. Report of the WHO–China joint mission on coronavirus
disease 2019 (COVID-19), February 28, 2020 [cited 2020 June 23]. https://wwwwhoint/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-reportpdf.
2020.
111. Adams
ML, Katz DL, Grandpre J. Population-Based Estimates of Chronic Conditions
Affecting Risk for Complications from Coronavirus Disease, United States. Emerg
Infect Dis. 2020;26(8).
112. Deng
X, Yang J, Wang W, Wang X, Zhou J, Chen Z, et al. Case fatality risk of the first
pandemic wave of novel coronavirus disease 2019 (COVID-19) in China. Clin
Infect Dis. 2020.
113. Carfi
A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in
Patients After Acute COVID-19. JAMA. 2020.
114. Long
B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19.
Am J Emerg Med. 2020; 38(7): 1504-7.
115. Hendren
NS, Drazner MH, Bozkurt B, Cooper LT, Jr. Descri-ption and Proposed Management
of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020; 141(23): 1903-14.
116. Wiersinga
WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission,
Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020.
117. Hascup
ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications?
Geroscience. 2020.
118. Desforges
M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses:
viral and cellular factors involved in neuroinvasiveness and neuropathogenesis.
Virus Res. 2014;194:145-58.